Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor

Experimental Cell Research

Volumn 326, Issue 2, 2014, Pages 267-279

  Oyanagi, Jun ^a,d   Kojima, Nako ^a   Sato, Haruki ^a   Higashi, Shouichi ^a   Kikuchi, Keiji ^b   Sakai, Katsuya ^c   Matsumoto, Kunio ^c   Miyazaki, Kaoru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d CANCER INSTITUTE   (Japan)

Author keywords

Cancer associated fibroblast (CAF); Collagen; HGF; TGF ; Tumor invasion; Tumor stroma

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; COLLAGEN GEL; FIBROBLAST GROWTH FACTOR; GALUNISERTIB; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CARCINOMA CELL; CELL INVASION; COCULTURE; DRUG EFFECT; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FETUS LUNG; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; LUNG FIBROBLAST; MICROTUBULE; PANCREAS CARCINOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION;

CANCER-ASSOCIATED FIBROBLAST (CAF); COLLAGEN; HGF; TGF-Β; TUMOR INVASION; TUMOR STROMA;

BENZAMIDES; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; COLLAGEN; DIOXOLES; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; MODELS, STATISTICAL; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904757553     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.04.009     Document Type: Article

References (43)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Sappiano A.O., Skalli O., Jackson B., Schurch W., Gabbiani G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 1988, 41:707-712.
3. Kalluri R., Zeissberg M. Fibroblasts in cancer. Nat. Rev. Cancer 2006, 6:392-401.
4. Micke P., Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer 2004, 45(Suppl 2):S163-S175.
5. Elenbaas B., Weinberg R.A. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 2001, 264:169-184.
6. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123:2229-2238.
7. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
8. Camps J.L., Chang S.M., Hsu T.C., Freeman M.R., Hong S.J., Zhau H.E., von Eschenbach A.C., Chung L.W. Fibroblast-mediated acceleration of human epithelial tumor growth in vivo. Proc. Natl. Acad. Sci. USA 1990, 87:75-79.
9. Picard O., Rolland Y., Poupon M.F. Fibroblast-dependent tumorigenicity of cells in nude mice: implication for implantation of metastases. Cancer Res. 1986, 46:3290-3294.
10. Pickup M., Novitskiy S., Moses H.L. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 2013, 13:788-799.
11. Zavadil J., Böttinger E.P. TGF-ß and epithelial-to-mesenchymal transitions. Oncogene 2005, 4:5764-5774.
12. Gorsch S.M., Memoli V.A., Stukel T.A., Gold L.I., Arrick B.A. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992, 52:6949-6952.
13. Friess H., Yamanaka Y., Büchler M., Ebert M., Beger H.G., Gold L.I., Korc M. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993, 105:1846-1856.
14. Wikström P., Stattin P., Franck-Lissbrant I., Damber J.E., Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 1998, 37:19-29.
15. Berking C., Takemoto R., Schaider H., Showe L., Satyamoorthy K., Robbins P., Herlyn M. Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res. 2001, 61:8306-8316.
16. Calone I., Souchelnytskyi S. Inhibition of TGFβ signaling and its implications in anticancer treatments. Exp. Oncol. 2012, 34:9-16.
17. Nakamura T., Nishizawa T., Hagiya M., Seki T., Shimonishi M., Sugimura A., Tashiro K., Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443.
18. Montesano R., Matsumoto K., Nakamura T., Orci L. Identification of a fibroblast derived epithelial morphogen as hepatocyte growth factor. Cell 1991, 67:29901-29908.
19. Nakamura T., Sakai K., Nakamura T., Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J. Gastroenterol. Hepatol. 2011, 6:188-202.
20. Trusolino L., Bertotti A., Comoglio P.M. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11:834-848.
21. Birchmeier C., Birchmeier W., Gherardi E., Vande Woude G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4:915-925.
22. Tomioka D., Maehara N., Kuba K., Mizumoto K., Tanaka M., Matsumoto K., Nakamura T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 2001, 61:7518-7524.
23. Oyanagi J., Ogawa T., Sato H., Higashi S., Miyazaki K. Epithelial-mesenchymal transition stimulates human cancer cells to extend microtubule-based invasive protrusions and suppresses cell growth in collagen gel. PLoS ONE 2012, 7:e53209.
24. Date K., Matsumoto K., Kuba K., Shimura H., Tanaka M., Nakamura T. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene 1998, 17:3045-3054.
25. Kikuchi K., Takahashi K. WAVE2- and microtubule-dependent formation of long protrusions and invasion of cancer cells cultured on three-dimensional extracellular matrices. Cancer Sci. 2008, 99:2252-2259.
26. Komiya E., Furuya M., Watanabe N., Miyagi Y., Higashi S., Miyazaki K. Elevated expression of angiomodulin (AGM/IGFBP-rP1) in tumor stroma and its roles in fibroblast activation. Cancer Sci. 2012, 103:691-699.
27. Yu W., O'Brien L.E., Wang F., Bourne H., Mostov K.E., Zegers M.M. Hepatocyte growth factor switches orientation of polarity and mode of movement during morphogenesis of multicellular epithelial structures. Mol. Biol. Cell 2003, 14:748-763.
28. Gherardi E., Birchmeier W., Birchmeier C., Vande Woude G. Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 2012, 12:89-103.
29. Blumenschein G.R., Mills G.B., Gonzalez-Angulo A.M. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J. Clin. Oncol. 2012, 30:3287-3296.
30. Ide T., Kitajima Y., Miyoshi A., Ohtsuka T., Mitsuno M., Ohtaka K., Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann. Surg. Oncol. 2007, 14:2600-2607.
31. Hasina R., Matsumoto K., Matsumoto-Taniura N., Kato I., Sakuda M., Nakamura T. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line. Br. J. Cancer 1999, 80:1708-1717.
32. Casey T.M., Eneman J., Crocker A., White J., Tessitore J., Stanley M., Harlow S., Bunn J.Y., Weaver D., Muss H., Plaut K. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study. Breast Cancer Res. Treat. 2008, 110:39-49.
33. Lewis M.P., Lygoe K.A., Nystrom M.L., Anderson W.P., Speight P.M., Marshall J.F., Thomas G.J. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br. J. Cancer 2004, 90:822-832.
34. De Wever O., Nguyen Q.D., Van Hoorde L., Bracke M., Bruyneel E., Gespach C., Mareel M. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004, 18:1016-1018.
35. Daly A.J., Mcllreavey L., Irwin C.R. Regulation of HGF and SDF-1 expression by oral fibroblasts-implications for invasion of oral cancer. Oral Oncol. 2008, 44:646-651.
36. Shimao Y., Nabeshima K., Inoue T., Koono M. Role of fibroblasts in HGF/SF-induced cohort migration of human colorectal carcinoma cells: fibroblasts stimulate migration associated with increased fibronectin production via upregulated TGF-beta1. Int. J. Cancer 1999, 82:449-458.
37. Fuxe J., Karlsson M.C. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin. Cancer Biol 2012, 22:455-461.
38. Halder S.K., Beauchamp R.D., Datta P.K. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 2005, 7:509-521.
39. Cheng N., Chytil A., Shyr Y., Joly A., Moses H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol. Cancer Res. 2008, 6:1521-1533.
40. Cheng N., Bhowmick N.A., Chytil A., Gorksa A.E., Brown K.A., Muraoka R., Arteaga C.L., Neilson E.G., Hayward S.W., Moses H.L. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene 2005, 24:5053-5068.
41. Matsumoto K., Tajima H., Okazaki H., Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J. Biol. Chem. 1992, 267:24917-24920.
42. Wang W., Li Q., Takeuchi S., Yamada T., Koizumi H., Nakamura T., Matsumoto K., Mukaida N., Nishioka Y., Sone S., Nakagawa T., Uenaka T., Yano S. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Clin. Cancer Res. 2012, 18:1663-1671.
43. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.